justbacked

Biopharma, Biotechnology, Life Science, Medical, Pharmaceutical

Ratio Therapeutics

Ratio Therapeutics raised $70M in a Series C announced on Jul 31, 2026, led by Eli Lilly, Catalio Capital Management, Bristol-Myers Squibb, Cornell University, Duquesne Family Office. Since then it has posted 4 roles (2 still open), the first 4 days after it. Another 2 open roles were posted before the announcement. With 4 open roles it is hiring more than 5% of the 83 Series C startups on JustBacked (median: 22). In total it has raised $160M over 3 rounds from 5 investors.

Roles posted per month since the round
  • August 20263
  • October 20261

From Ratio Therapeutics's own hiring system, by posting date. Tracked since Oct 4, 2026; roles that closed before then aren't counted.

Ratio Therapeutics is a clinical-phase pharmaceutical company that develops radiopharmaceuticals for solid tumors.

Why join Ratio Therapeutics?

The bet: one targeting platform, Ratio Therapeutics' Trillium, can both image and treat tumors, so a single scan could pick the patients and the drug. If it works, Boston-based radiopharmaceuticals could move from a niche option to a routine tool against many solid tumors. Eli Lilly and Bristol-Myers Squibb back a $70M Series C, bigger than 34% of rounds at its stage this half, for a clinical-phase company.

JustBacked's take, based on Ratio Therapeutics's own site and its funding and hiring data.

Series C · $70M · 113d agoratiotx.com

Hiring velocity

Open roles
4
Added, 30 days
+0
Added, 7 days
+0
Closed, 30 days
4
Raised
113 days ago
Led by
Eli Lilly, Catalio Capital Management, Bristol-Myers Squibb, Cornell University, Duquesne Family Office
Team size
11-50
HQ
Boston, Massachusetts, United States
Newest role
1mo ago
Tracked since
Oct 4, 2026

Where they're hiring

Science1
Operations1
Engineering1

Open roles at Ratio Therapeutics

Source: ratiotx.com, checked daily.